Literature DB >> 26841005

Virology, serology, and demography of hepatitis E viremic blood donors in South East England.

Richard S Tedder1,2,3, Kate I Tettmar1,2, Su R Brailsford1,4, Bengu Said5, Ines Ushiro-Lumb1,2, Alan Kitchen1, Dilys Morgan5, Sam Lattimore4, Joanne Tossell1, Samreen Ijaz2, Patricia E Hewitt1.   

Abstract

BACKGROUND: Hepatitis E virus (HEV) Genotype 3 (G3) in England comprises two principal phylogenetic groups (Group 1 and Group 2) and can be transmitted by transfusion. Unselected screening identified 79 viremic donors; 76 participated in a follow-up study. STUDY DESIGN AND METHODS: Viral RNA dynamics, phylogenetics, and seroconversion were characterized in the donors. Detailed demographic, travel, clinical, and lifestyle questionnaires were undertaken.
RESULTS: The majority of viremic individuals (57/79) were seronegative at time of donation but all seroconverted. Viremia was short-lived, with a median of 6.5 weeks to confirmed viral clearance. All infections were acquired in the United Kingdom and were G3, with Group 2 viruses predominating (43/54; 80%). Infection was associated with some clinical symptoms both at and after donation (8/77; 10%). Viral loads and symptoms were more pronounced in Group 1 infections. There was no serologic evidence of reinfection. Donors were more commonly male (p = 0.002); both male and female donors were older than comparator donors. Animal contact was unlikely to be the source of infection. Consumption of chicken and pig meat was common to all infected donors; processed pig meat was most commonly purchased from one particular retail chain.
CONCLUSION: Viremic donors represent primary infection in older members of the community and reflect a widespread zoonotic in the United Kingdom. The two phylogenetic groups of HEV G3 display different pathogenicity and the more common Group 2 appears less adapted to humans. There are no objective demographic criteria that can identify donors at enhanced HEV risk.
© 2016 AABB.

Entities:  

Mesh:

Year:  2016        PMID: 26841005     DOI: 10.1111/trf.13498

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  13 in total

1.  Disparities in detection of antibodies against hepatitis E virus in US blood donor samples using commercial assays.

Authors:  Mohammad Zafrullah; Xiugen Zhang; Coleen Tran; Megan Nguyen; Saleem Kamili; Michael A Purdy; Susan L Stramer
Journal:  Transfusion       Date:  2018-03-09       Impact factor: 3.157

2.  First report of hepatitis E virus viremia in healthy blood donors from Nepal.

Authors:  Birendra Prasad Gupta; Thupten K Lama; Anurag Adhikari; Ananta Shrestha; Ramanuj Rauniyar; Binay Sapkota; Sandeep Thapa; Smita Shrestha; Pawan Prasad Gupta; Krishna Das Manandhar
Journal:  Virusdisease       Date:  2016-08-10

Review 3.  Blood Donor Screening for Hepatitis E Virus in the European Union.

Authors:  Fiona Boland; Auxiliadora Martinez; Louise Pomeroy; Niamh O'Flaherty
Journal:  Transfus Med Hemother       Date:  2019-03-14       Impact factor: 3.747

4.  Hepatitis E Virus Genotype 3 Genomes from RNA-Positive but Serologically Negative Plasma Donors Have CUG as the Start Codon for ORF3.

Authors:  Heléne Norder; Cristina Galli; Ellen Magnil; Per Sikora; Elisabet Ekvärn; Kristina Nyström; Lars O Magnius
Journal:  Intervirology       Date:  2018-10-02       Impact factor: 1.763

5.  Pork products associated with human infection caused by an emerging phylotype of hepatitis E virus in England and Wales.

Authors:  B Said; M Usdin; F Warburton; S Ijaz; R S Tedder; D Morgan
Journal:  Epidemiol Infect       Date:  2017-07-31       Impact factor: 4.434

6.  Long-term HEV carriers without antibody seroconversion among eligible immunocompetent blood donors.

Authors:  Gui-Ping Wen; Chang-Rong Chen; Xiu-Yu Song; Zi-Min Tang; Wen-Fang Ji; Si-Ling Wang; Ke Zhang; Jun Zhang; Shan-Hai Ou; Zi-Zheng Zheng; Ning-Shao Xia
Journal:  Emerg Microbes Infect       Date:  2018-07-05       Impact factor: 7.163

7.  Hepatitis E virus infection in Europe: surveillance and descriptive epidemiology of confirmed cases, 2005 to 2015.

Authors:  Esther J Aspinall; Elisabeth Couturier; Mirko Faber; Bengü Said; Samreen Ijaz; Lara Tavoschi; Johanna Takkinen; Cornelia Adlhoch
Journal:  Euro Surveill       Date:  2017-06-29

8.  Donor-Derived Genotype 4 Hepatitis E Virus Infection, Hong Kong, China, 2018.

Authors:  Siddharth Sridhar; Vincent C C Cheng; Shuk-Ching Wong; Cyril C Y Yip; Shusheng Wu; Anthony W I Lo; Kit-Hang Leung; Winger W N Mak; Jianpiao Cai; Xin Li; Jasper F W Chan; Susanna K P Lau; Patrick C Y Woo; Wai-Ming Lai; Tze-Hoi Kwan; Timmy W K Au; Chung-Mau Lo; Sally C Y Wong; Kwok-Yung Yuen
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883

9.  Hepatitis E virus in blood donors in England, 2016 to 2017: from selective to universal screening.

Authors:  Heli Harvala; Patricia E Hewitt; Claire Reynolds; Callum Pearson; Becky Haywood; Kate I Tettmar; Ines Ushiro-Lumb; Susan R Brailsford; Richard Tedder; Samreen Ijaz
Journal:  Euro Surveill       Date:  2019-03

10.  Seroprevalence of viral hepatitis A, B, C, D and E viruses in the Hormozgan province southern Iran.

Authors:  Mohammad Amin Behzadi; Victor Hugo Leyva-Grado; Mandana Namayandeh; Atoosa Ziyaeyan; Roya Feyznezhad; Hedayat Dorzaban; Marzieh Jamalidoust; Mazyar Ziyaeyan
Journal:  BMC Infect Dis       Date:  2019-12-03       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.